Literature DB >> 25697896

Increased number of forkhead box P3+ tumor-infiltrating lymphocytes correlates with high preoperative albumin level and better survival in patients with stage II or III colorectal cancer.

Dong-liang Wang1, Yan-yan Liu, Yuan-long Gu, Yu Qin, Hong-fei Ji, Li-hua Wu, Ning Qi, Dan Su, Sun-hui Huang, Yan-qiao Zhang.   

Abstract

Tumor-infiltrating lymphocytes (TILs) that test positive for forkhead box P3 (FOXP3) and elevated preoperative serum albumin levels have been positively associated with survival in colorectal cancer (CRC). This study aimed to investigate correlations among FOXP3+ TILs, preoperative serum albumin, overall survival, and other clinicopathological features of CRC patients. Surgical specimens from 340 stage II-III CRC patients were stained immunohistochemically for the presence of FOXP3+ TILs. Serum albumin levels were determined using an automatic biochemistry analyzer. Associations between various clinicopathological features and patient survival were analyzed via a Cox proportional hazards regression model. The correlation between FOXP3+ TILs and preoperative serum albumin was assessed using Pearson's correlation analysis. Survival curves were constructed by the Kaplan-Meier method. A high FOXP3+ TIL density (>15/five high-power fields), elevated preoperative serum albumin (≥35 g/L), and proximal colon carcinoma were significantly associated with better survival, and high FOXP3+ TIL number and elevated preoperative serum albumin were independent predictors of better survival. The correlation between the number of FOXP3+ TILs and preoperative serum albumin level was significant but neither of these correlated with gender, age, tumor size, tumor differentiation, mucinous tumor, T4 stage, postoperative chemotherapy, or tumor location. Our findings suggest that increased FOXP3+ TILs and high preoperative serum albumin levels are independent prognostic markers for improved survival in CRC patients. Furthermore, the number of FOXP3+ TILs correlates with preoperative serum albumin levels in these patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25697896     DOI: 10.1007/s13277-015-3206-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  34 in total

1.  The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.

Authors:  Dominik Wolf; Anna M Wolf; Holger Rumpold; Heidi Fiegl; Alain G Zeimet; Elisabeth Muller-Holzner; Martina Deibl; Guenther Gastl; Eberhard Gunsilius; Christian Marth
Journal:  Clin Cancer Res       Date:  2005-12-01       Impact factor: 12.531

2.  Prognostic significance of tumor-infiltrating lymphocytes for patients with colorectal cancer.

Authors:  Jung Wook Huh; Jae Hyuk Lee; Hyeong Rok Kim
Journal:  Arch Surg       Date:  2012-04

3.  Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival.

Authors:  Jane A Read; S T Boris Choy; Philip J Beale; Stephen J Clarke
Journal:  Nutr Cancer       Date:  2006       Impact factor: 2.900

4.  Low preoperative serum albumin in colon cancer: a risk factor for poor outcome.

Authors:  Cheng-Chou Lai; Jeng-Fu You; Chien-Yuh Yeh; Jinn-Shiun Chen; Reiping Tang; Jeng-Yi Wang; Chih-Chien Chin
Journal:  Int J Colorectal Dis       Date:  2010-12-29       Impact factor: 2.571

5.  Prognostic significance of tumor infiltrating lymphocytes in melanoma.

Authors:  Alison L Burton; Brent A Roach; Michael P Mays; Andrea F Chen; Brooke A R Ginter; Abbey M Vierling; Charles R Scoggins; Robert C G Martin; Arnold J Stromberg; Lee Hagendoorn; Kelly M McMasters
Journal:  Am Surg       Date:  2011-02       Impact factor: 0.688

6.  Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.

Authors:  Rebecca P Petersen; Michael J Campa; Justin Sperlazza; Debbi Conlon; Mary-Beth Joshi; David H Harpole; Edward F Patz
Journal:  Cancer       Date:  2006-12-15       Impact factor: 6.860

7.  Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer.

Authors:  Hiroyuki Suzuki; Nobuhito Chikazawa; Takehiko Tasaka; Junji Wada; Akio Yamasaki; Yoshiki Kitaura; Masae Sozaki; Masao Tanaka; Hideya Onishi; Takashi Morisaki; Mitsuo Katano
Journal:  Cancer Immunol Immunother       Date:  2009-11-12       Impact factor: 6.968

8.  Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer.

Authors:  Giuseppe Perrone; Pier Adelchi Ruffini; Vincenzo Catalano; Cathie Spino; Daniele Santini; Pietro Muretto; Chiara Spoto; Costantino Zingaretti; Valerio Sisti; Paolo Alessandroni; Paolo Giordani; Andrea Cicetti; Silvia D'Emidio; Sergio Morini; Annamaria Ruzzo; Mauro Magnani; Giuseppe Tonini; Carla Rabitti; Francesco Graziano
Journal:  Eur J Cancer       Date:  2008-07-09       Impact factor: 9.162

9.  A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss.

Authors:  D C McMillan; S J Wigmore; K C Fearon; P O'Gorman; C E Wright; C S McArdle
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

10.  The relationship between hypoalbuminaemia, tumour volume and the systemic inflammatory response in patients with colorectal liver metastases.

Authors:  R Al-Shaiba; D C McMillan; W J Angerson; E Leen; C S McArdle; P Horgan
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

View more
  2 in total

1.  A Nomogram to Predict Adequate Lymph Node Recovery before Resection of Colorectal Cancer.

Authors:  Zhen-Yu Zhang; Cong Li; Wei Gao; Xiao-Wei Yin; Qi-Feng Luo; Nan Liu; Shiva Basnet; Zhen-Ling Dai; Hai-Yan Ge
Journal:  PLoS One       Date:  2016-12-16       Impact factor: 3.240

2.  Prognostic significance of the pretreatment prognostic nutritional index in patients with epithelial ovarian cancer.

Authors:  Naoko Komura; Seiji Mabuchi; Eriko Yokoi; Kotaro Shimura; Mahiru Kawano; Yuri Matsumoto; Tadashi Kimura
Journal:  Oncotarget       Date:  2019-06-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.